Ursula A. Matulonis, MD, on Various Advancements in Gynecologic Cancers Presented at SGO 2021

Video

CancerNetwork® discussed updates in the treatment of gynecologic cancers with Ursula A. Matulonis, MD.

CancerNetwork® sat down with Ursula A. Matulonis, MD, who is chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute as well as a professor of medicine at Harvard Medical School, to discuss data presented at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer and what abstracts she believes have the greatest potential to shift the treatment paradigm in various gynecologic cancers.

She first pointed to data presented from the KEYNOTE-775 trial (NCT03517449), which showed that pembrolizumab (Keytruda) plus lenvatinib (Lenvima) administered to patients with advanced, metastatic, or recurrent endometrial cancer who had previously received 1 prior platinum-based regimen in any setting resulted in improved progression-free survival (PFS) and overall survival (OS) versus those treated with physician’s choice therapy.

She also mentioned updated results of the phase 2 KEYNOTE-158 study (NCT02628067) of pembrolizumab in the treatment of advanced cervical cancer as well as a study examining tumor infiltrating lymphocytes, or TILS (LN-145), in recurrent cervical cancer.1,2

Transcription:

They are a lot of practice-changing abstracts being presented. Obviously, KEYNOTE-775 was presented showing improvement of pembrolizumab with lenvatinib in women with recurrent endometrial cancer, mostly in mismatch-repair proficient tumors. That’s practice changing. I gave up a distillation of that on Friday and it really opens up the next steps for improvement in outcomes for women with endometrial cancer and puts a spotlight on this cancer that it’s never [had] before. That’s really exciting for me to see.

There was also data on pembrolizumab presented yesterday, [updating] results in recurrent cervix cancer. Then [the was an abstract about] tumor infiltrating lymphocytes also presented for cervical cancer, so a lot of really great abstracts are being presented.

References

1. Cheol Chung H, Delord JP, Perets R, et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. Presented at: Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. March 22-25, 2021.

2. Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. Presented at: Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. March 22-25, 2021.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content